Pipeline

Medium without sidebar

Vaxeal mise sur leurs spécificités pour licencier ses produits aux pharmas

“Le modèle d’affaires indirect… VAXEAL. L’entreprise active dans les vaccins thérapeutiques mise sur leurs spécificités pour licencier ses produits aux pharmas.” in: L’AGEFI SUISSE, vendredi 5 avril 2013 (Page 7). Télécharger le document Ahmed Bouzidi, presented at the Stakeholder Workshop for SMEs organized by the IMI →← Vaxeal awarded by Genopole for its cutting edge vaccine technologies
  • Posted by Elliot Willcox
  • On 5 April 2013
  • 0 Comments
  • Read More

VAXEAL AND FINLAY SIGN R&D AGREEMENT

Vaxeal and Finlay Institute Sign an R&D Agreement Covering a Novel Generation of Immuno-stimulants and Delivery Systems 26 February 2013 La Havana, 26 February 2013 – Vaxeal Holding SA announced today that it has signed a Research and Development agreement with the Finlay Institute (Havana, Cuba). Vaxeal and Finlay Institute will co-develop several Vaxeal’s LSP-based vaccines […]
  • Posted by Elliot Willcox
  • On 26 February 2013
  • 0 Comments
  • Read More

VAXEAL AWARDED BY GENOPOLE

Vaxeal awarded by Genopole for its cutting edge vaccine technologies 6 February 2013Evry, 6 February 2013 – Vaxeal Holding today announced that Dr Jerome Kerzerho, Director R&D of the company, presented Vaxeal R&D at the Welcome Session organized by Genopole.  This event took place in the conference room of Genopole in Evry in presence of […]
  • Posted by Elliot Willcox
  • On 6 February 2013
  • 0 Comments
  • Read More

AHMED BOUZIDI, IMI SME WORKSHOP STAKEHOLDER

Ahmed Bouzidi, presented at the Stakeholder Workshop for SMEs organized by the IMI Brussels, 19 September 2012 – Vaxeal Holding today announced that Dr Ahmed Bouzidi, CEO of the company, made an oral presentation entitled “EUROPEAN BIOTECH SMEs AND THE FUTURE SOCIETAL CHALLENGES” at the Stakeholder Workshop with Small and Medium-Sized Enterprises, Public-Private Partnership in […]
  • Posted by Elliot Willcox
  • On 19 September 2012
  • 0 Comments
  • Read More

Monthly Archives: June 2012

26 June 2012 Brussels, 26 June 2012 – At the occasion of its General Assembly held, as part of the EFPIA Annual Meeting, Ahmed Bouzidi, CEO of Vaxeal Holding has been appointed as board member of EBE (European Biopharmaceutical Enterprises). For more information, please visit EBE website: www.ebe-biopharma.org About Vaxeal Holding SA Created in 2009, Vaxeal […]
  • Posted by Elliot Willcox
  • On 26 June 2012
  • 0 Comments
  • Read More

AHMED BOUZIDI APPOINTED EVM R&D TASK FORCE MEMBER

Ahmed Bouzidi has been appointed as member of the R&D task force of the European Vaccine Manufacturers (EVM) 2 May 2012Brussels, 2 May 2012 – At the occasion of its General Assembly, Ahmed Bouzidi, CEO of Vaxeal Holding has been appointed as member of the R&D task force of the European Vaccine Manufacturers (EVM). EVM […]
  • Posted by Elliot Willcox
  • On 2 May 2012
  • 0 Comments
  • Read More

VAXEAL APPOINTS Dr. JEROME KERZERHO R&D DIRECTOR

2 April 2012Vevey, 2 April 2012 – Vaxeal Holding SA, a Swiss company developing innovative therapeutic vaccines for the treatment of cancer and infectious diseases, is pleased to announce today that Jerome Kerzerho, PhD. has joined the company as Director of Research & Development.Dr. Kerzerho brings a significant amount of skills in the field of […]
  • Posted by Elliot Willcox
  • On 2 April 2012
  • 0 Comments
  • Read More